

### Date: 19.05.2022

| <ol> <li>BSE Limited</li> <li>P.J. Towers, Dalal Street,</li> <li>Mumbai – 400001</li> </ol> | <ol> <li>Metropolitan Stock Exchange of India Limited<br/>Vibgyor Towers, 4<sup>th</sup> floor, Plot No. C62, Opp. Trident<br/>Hotel, BandraKurla Complex, Bandra (E), Mumbai-<br/>400088</li> </ol> |
|--|--|
| Mumbai – 400001  | 400098   |

Dear Sir/Madam,

Sub: Outcome of board meeting held on 19.05.2022

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of DrHabeebullah Life Sciences Limited held on Thursday, the 19<sup>th</sup> day of May, 2022 at 3:30 p.m. at the registered office of the Company, the following were considered and approved by the Board:

1. Audited financial results for the quarter and year ended 31.03.2022.

-

2. Audit Report along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2022.

The meeting concluded at 4.30 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Sincerely, For Dr Habeebullah Life Sciences Limited

K.Krishnam Raju Chairman & Whole-Time Director (DIN: 00874650)

## Dr Habeebullah Life Sciences Ltd

**Regd. Off** & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082 .**CIN No.**: L85110TG1996PLC099198. Email: <u>cs@drhlsl.com</u>, <u>info@drhlsl.com</u>, <u>pcproductsindia@gmail.com</u> **Contact No.**: **9490424639**, Website : www.drhlsl.com

To,

|       |  |                                 |  |   | IDED 31ST MARCH      |                    |
|-------|--|---------------------------------|--|---|----------------------|--------------------|
|       |  |                                 |  |   |                      | (INR In Lakhs)     |
|       |  | 3 Months<br>Ended<br>31/03/2022 | Quarter Ended<br>Preceeding<br>3 Months<br>Ended<br>31/12/2021 | Corsp. 3<br>months<br>ended<br>31/03/2021 | Year E<br>31/03/2022 | nded<br>31/03/2021 |
|       |  | Audited                         | Unaudited  | Audited                                   | Audited              | Audited            |
|       | Revenue from Operations  | 2.25                            | -  | -   | 2.25                 | 1.30               |
| I     | Other Income   | 178.44                          | 4.17   | 3.85                                      | 190.62               | 14.77              |
| п     | Total Revenue (I+II)   | 180.69                          | 4.17   | 3.85                                      | 192.87               | 16.07              |
| V     | Expenses   |                                 |  |   |                      |                    |
|       | Purchases  | 2.16                            | -  | -   | 2.16                 | -                  |
|       | Cost of Material Consumed  |                                 | -  |   | 12.02                | 0.19               |
|       | Changes in inventories   | 12.92                           | -  | -   | 12.92                | -                  |
|       | Employee benefits expense  | 5.28                            | 2.76   | 0.78                                      | 11.47                | 33.17              |
|       | Depreciation and Amortisation expense  | 0.13                            | 0.13   | 0.17                                      | 0.54                 | 0.96               |
|       | Other Expenses   | 2.33                            | 2.95   | 5.01                                      | 15.94                | 58.72              |
|       | Total Expenses   | 22.82                           | 5.84   | 5.96                                      | 43.03                | 93.04              |
| V     | Profit/(Loss) from before Exceptional  | 157.07                          | (1 (7))  | (2.11)                                    | 149.84               | (76.97)            |
|       | Items and tax (I-IV)   | 157.87                          | (1.67)   | (2.11)                                    | 149.04               | (70.57)            |
| VI    | Exceptional Items  | -                               |  | -   | -                    |                    |
| VII   | Profit/(Loss) before tax (V-VI)  | 157.87                          | (1.67)   | (2.11)                                    | 149.84               | (76.97)            |
| VIII  | Tax Expense:   |                                 |  |   |                      |                    |
|       | Current Tax  | -                               | -  | -   | (4)                  |                    |
|       | Deferred Tax   |                                 | -  | -   |                      |                    |
| x     | Profit/ (Loss) for the period from   |                                 |  |   |                      |                    |
|       |  | 157.87                          | (1.67)   | (2.11)                                    | - 149.84             | (76.97             |
| x     | Continuing operations (VII-VIII)<br>Pront/ (Loss) from discontinuing   | 107.07                          | (1.077   | (2.22)                                    |                      |                    |
| ~     | operations   |                                 | -  |   | -                    |                    |
| XI    |  |                                 |  |   |                      |                    |
|       | Tax Expense of discontinuing operations  | -                               | -  | ×   | -                    |                    |
| XII   |  |                                 |  |   |                      |                    |
|       | Profit/ (Loss) for the period from   |                                 |  |   |                      |                    |
|       | discontinuing operations after tax (X-XI)  |                                 |  |   |                      |                    |
| XIII  | Profit/ (Loss) for the period (IX+XII)   | 157.87                          | (1.67)   | (2.11)                                    | 149.84               | (76.97)            |
| VIV   | Other Comprehensive Income<br>A) (i) Items that will not be reclassified to<br>profit or loss (ii) Income Tax related to<br>items that will not be relclassified to<br>profit or loss<br>(B) (i) Items that will be reclassifed to<br>profit or loss (ii) Income Tax relating to |                                 |  | 12.67                                     |                      | 14.08              |
| XV    | period (XIII+XIV) (Comprising Profit   |                                 |  |   |                      |                    |
|       | (loss) and Other Comprehensive Income  |                                 |  |   |                      |                    |
|       | for the Period)  | 157.87                          | (1.67)   | 10.56                                     | 149.84               | (62.89             |
| XVI   | Comprehensive Income attributable to   | 107.07                          | (2.0.7)  |   |                      |                    |
|       | Non Controlling Interest   |                                 | -  |   |                      |                    |
| XVII  | Comprehensive Income attributable to   |                                 |  |   |                      |                    |
| AAN   | Owners of the company  | 157.87                          | (1.67)   | 10.56                                     | 149.84               | (62.89             |
|       | owners of the company  |                                 |  |   |                      |                    |
| XVIII | Earnings Per Equity Share (For<br>Continuing Operations) (Face Value INR   |                                 |  |   |                      |                    |
|       | 10/- each)<br>1) Basic   | 1.07                            | (0.01)   | 0.07                                      | 1.01                 | (0.42              |
|       | 2) Diluted   | 1.07                            | (0.01)   | 0.07                                      | 1.01                 | (0.42              |
| VIII  |  | 1.07                            | (0.01)   | 0.07                                      | 1.01                 | (0.42              |
| KIX   | Earnings Per Equity Share (For<br>Discontinued Operations) (Face Value<br>INR 10/- each) 1) Basic<br>2) Diluted  |                                 |  |   |                      |                    |
| κx    | Earnings Per Equity Share (For Continued<br>and Discontinued Operations)(Face Value<br>INR 10/- each)  |                                 |  |   |                      |                    |
|       | 1) Basic   | 1.07                            | (0.01)   | 0.07                                      | 1.01                 | (0.42              |
|       | 2) Diluted   | 1.07                            | (0.01)   | 0.07                                      | 1.01                 | (0.42              |
| XXI   | Paid Up Equity Share Capital (Face Value   | 2.07                            | (0.02)   |   |                      |                    |
|       | of INR 10/- per share)   | 1,480.87                        | 1,480.87   | 1,480.87                                  | 1,480.87             | 1,480.87           |

e.\$

LIF.

Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Thursday, May 19th, 2022.

2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).

3. During this Quarter the compnay has restarted the business as per objects in a small way and expected to enter the Bio-Pharma business in the coming months.

4. The figures of the previous year/periods have been re-grouped/re-classifed, whenever necessary, for the purpose of comparison.

5. The figures of the current quarter ended March 31, 2022 and the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.

6. The Company has only one reportable segment i.e., Heath Care Sector. Hence, the separate disclosure on Segment information is not required.

7. The results are also available on the webiste of the Company www.drhlsl.com


Place : Hyderabad Date: 19/05/2022 K Krishnam Raju Executive Chairman (DIN 00874650).

For DR HABEEBULLAH LIFE SCIENCES LIMITED

LIFES

-

| Particulars     STANDALONE       ASSETS     31/03/2022     31/03/2022       ASSETS     31/03/2022     31/03/2022       ASSETS     31/03/2022     31/03/2022       ASSETS     1     1       Non Current Assets     1.25     1       a Property, Plant and Equipments     1.25     1       b Capital Work In Progress     -     -       c Investment Property     -     -       d Goodwill     -     -       e Other Intangable Assets under development     325.95     322       g Biological assets other than bearer plants     -     -       h Financial Assets:     -     -       i Invage Receivables     -     -     -       ii I cans     -     -     -       i Others     200.25     200     -       j Other S     200.25     200     -       j Other Non Current Assets     -     -     -       j Other Non Current Assets     -     -     -       i Investments     -     -     -     -       i Investments     -     -     -     -       i Investments     -     -     -     -       i Deferred Tax Assets (net)     -     -     -     - <th>Statement of Assets and Liabi</th> <th>lities</th> <th></th>  | Statement of Assets and Liabi   | lities  |                |
|--|---|---|----------------|
| Particulars31/03/202231/03/2022ASSETS1Non Current Assetsa Property, Plant and Equipments1.25b Capital Work In Progress-c Investment Prpoerty-d Goodwil-e Other Intangable Assets under development325.95f Intangable Assets under development325.95g Biological assets other than bearer plants-h Financial Assets:-i Investments487.06ii Icoans-vi Others200.25vi Others200.25vi Others-vi Others-i Deferred Tax Assets (net)-j Other Non Current Assets-ii Irade Receivables-ii Irade Receivables-ii Irade Receivables-ii Other S-j Other Non Current Assets-ii Irade Receivables-ii Irade Receivables-ii Irade Receivables-ii Irade Receivables-ii Irade Receivables-ii Irade Receivables-vi Other financial assets-vi Other financial assets-vi Other Current Assets (net)-vi Other Current Assets-vi Other Current Assets-ii Irade Receivables-vi Other Current Assets-vi Other Current Assets-ii Regerves and Surplus-ii Share Warrants-ii Reserves and Surplus- <t< th=""><th></th><th></th><th>(INR. in Lakhs</th></t<>  |   |   | (INR. in Lakhs |
| ASSETS       31/03/2022       31/03/2022         ASSETS       1       Non Current Assets       1.25         a Property, Plant and Equipments       1.25       -         b Capital Work In Progress       -       -         c Investment Property       -       -         d Goodwill       -       -         e Other Intangable Assets under development       325.95       322         g Biological assets other than bearer plants       -       -         h Financial Assets:       -       -         i Investments       4487.06       488         ii Icans       -       -         i/ Others       200.25       200         v Loans       -       -       -         j Other Non Current Assets       -       -       -         i Investments       -       -       1.018         i Cash and Advances       -       -       1.029         v Other financial assets       5  | Destinution   | STAND   | ALONE          |
| 1       Non Current Assets       1.25         a Property, Plant and Equipments       1.25         b Capital Work In Progress       -         c Investment Property       -         d Goodwill       -         e Other Intangable Assets under development       325.95         g Biological assets other than bearer plants       -         h Financial Assets:       -         in Investments       487.06         iii I rade Receivables       -         iii Tade Receivables       -         vi Others       200.25         vi Dans       -         vi Others       200.25         j Other Non Current Assets       -         i Deferred Tax Assets (net)       -         j Other Non Current Assets       -         a Inventories       -         j Inarcial Assets       -         i Investments       0.93         ii Trade Receivables       212.45         vi Dans and Advances       -         vi Dans and Advances       -         vi Dans and Advances       -         vi Date financial assets       -         j Other Current Assets (net)       -         j Other Financial assets       - <tr< th=""><th>Particulars</th><th>31/03/2022</th><th>31/03/2021</th></tr<>   | Particulars   | 31/03/2022  | 31/03/2021     |
| a Property, Plant and Equipments 1.25<br>b Capital Work In Progress  | ASSETS  |   |                |
| b Capital Work In Progress<br>c Investment Property<br>d Goodwill<br>e Other Intangable Assets<br>f Intangable Assets under development<br>g Biological assets other than bearer plants<br>h Financial Assets:<br>i Investments<br>i Investments<br>i Trade Receivables<br>ii Others<br>Deferred Tax Assets (net)<br>j Other Non Current Assets<br>Investments<br>2 Current Assets<br>i Investments<br>i Investments<br>2 Current Assets<br>i Investments<br>2 Current Assets<br>i Investments<br>2 Current Assets<br>i Investments<br>2 Current Assets<br>i Investments<br>1 Investments<br>2 Current Assets<br>1 Investments<br>2 Current Assets<br>1 Investments<br>2 Current Assets<br>1 Investments<br>1 Investments<br>2 Current Assets<br>1 Investments<br>2 Current Tax Assets (net)<br>0 Other Current Assets<br>2 Current Tax Assets (net)<br>0 Other Current Assets<br>1 Advances<br>2 Current Assets<br>1 Advances<br>2 Current Assets<br>1 Advances<br>2 Current Assets<br>1 Advances<br>2 Current Assets<br>2 Curre   | 1 Non Current Assets  |   |                |
| c Investment Prpoerty<br>d Goodwill<br>e Other Intangable Assets<br>f Intangable Assets under development<br>f Intangable Assets under development<br>f Intangable Assets under development<br>f Intangable Assets to ther than bearer plants<br>h Financial Assets:<br>i Investments<br>i Investments<br>v Others<br>v Others<br>v Chans<br>z Current Assets<br>a Inventories<br>z Current Assets<br>i Investments<br>i Investments<br>z Current Assets<br>i Investments<br>i Investments<br>z Current Assets<br>i Investments<br>i Investments<br>z Current Assets<br>i Investments<br>z Current Assets<br>z Current Assets<br>i Investments<br>z Current Assets<br>z  | a Property, Plant and Equipments  | 1.25  | 1.7            |
| d Goodwill   | b Capital Work In Progress  | -   | -              |
| e Other Intangable Assets f Intangable Assets under development g Biological assets other than bearer plants h Financial Assets: i Irvestments i Irade Receivables ii Trade Receivables ii Cans i Deferred Tax Assets (net) j Others 2 Current Assets a Inventories a Inventories current Assets i Irvestments i Irves   | c Investment Prpoerty   |   | -              |
| f       Intangable Assets under development       325.95       32         g       Biological assets other than bearer plants       -       -         h       Financial Assets:       -       -         i Investments       487.06       48         ii Tade Receivables       -       -         iii Loans       -       -         vo Others       200.25       200         vo Others       200.25       200         vo Others       -       -         j Other Non Current Assets       -       -         a Investories       -       -       1         j Investories       -       -       1         i Investories       -       -       1         i Investories       -       -       -         vo Loans and Advances       0.9  | dGoodwill   | -   | -              |
| g Biological assets other than bearer plants<br>h Financial Assets:<br>i Investments<br>i Irade Receivables<br>2 Current Assets<br>i Investments<br>2 Current Assets<br>i Investments<br>2 Current Assets<br>i Investments<br>2 Current Assets<br>i Investments<br>2 Current Assets<br>i Investments<br>5 Financial Assets<br>i Investments<br>5 Financial Assets<br>i Investments<br>5 Corrent Tax Assets (net)<br>5 Current Tax Assets (net)<br>5 Current Assets<br>5 Corrent Tax Assets (net)<br>5 Current Assets<br>5 Corrent Tax Assets (net)<br>5 Current Assets<br>5 Corrent Tax Assets (net)<br>5 Current Tax Assets<br>5 Current Tax Assets   | e Other Intangable Assets   |   | -              |
| h Financial Assets:<br>i Investments i Investments i Trade Receivables ii Trade Receivables ii Trade Receivables ii Cohres V Others V Others V Loans V Others V Loans V Others V Ioans and Advances V Ioans Advances V Ioans Advances V Ioans Advances V Ioans  | f Intangable Assets under development   | 325.95  | 325.9          |
| i Investments 487.06 48<br>ii Trade Receivables  | g Biological assets other than bearer plants  | -   |                |
| ii Trade Receivables ii Loans ii Conters i Others ii Others ii Others ii Deferred Tax Assets (net) j Other Non Current Assets ii Cash and Cash Equivalents ii Cash and Cash Equivalents ii Cash and Cash Equivalents ii Cash and Advances ii Cash and Advances ii Carrent Tax Assets (net) d Other Current Assets I Current A   | h Financial Assets:   |   | -              |
| ii Loans   | i Investments   | 487.06  | 487.0          |
| v       Others       200.25       200         v       Loans       -       -         vi       Others       -       -         i       Deferred Tax Assets (net)       -       -         j       Other Non Current Assets       -       -         z       Inventories       -       -         b       Financial Assets       -       -         inventories       -       -       -         ii Trade Receivables       212.45       212         ii Cash and Cash Equivalents       0.93       -         v       Loans and Advances       -       -         v       Loans and Advances       134.00       134         v       Other financial assets       -       -       -         c       Current Tax Assets (net)       -       -       -         d       Other Current Assets       705.51       703       -         d       Current Assets       -       -       -       - <tr< td=""><td>ii Trade Receivables</td><td>-</td><td>_</td></tr<>  | ii Trade Receivables  | -   | _              |
| v Loans<br>i Others<br>i Others<br>i Deferred Tax Assets (net)<br>j Other Non Current Assets<br>Total Non Current Assets<br>Total Non Current Assets<br>I,014.51<br>1,018<br>-<br>i Other Non Current Assets<br>a Inventories<br>i Investments<br>i Investments<br>i Trade Receivables<br>i Cash and Cash Equivalents<br>v Loans and Advances<br>v Loans and Advances<br>i Current Tax Assets (net)<br>d Other financial assets<br>c Current Tax Assets (net)<br>d Other Current Assets<br><b>Total Current Assets</b><br><b>Total </b> | ii Loans  | -   | -              |
| vi     Others     -       i     Deferred Tax Assets (net)     -       j     Other Non Current Assets     -       Z     Current Assets     1,014.51       a     Inventories     -       b     Financial Assets     -       i     Inventories     -       i     Inventories     -       i     Inventories     -       i     Investments     -       ii     Cash and Cash Equivalents     0.93       v     Bank balances other than above     -       v     Loans and Advances     134.00       ii     Other Current Assets     305.54       d     Other Current Assets     -       d     Other Current Assets     -       t     Total Current Assets     -       t     Total Assets     1,720.02       t     Equity     -       a     Equity Share Capital     1,480.87       b     Other Equity     -       i     Share Warrants     -       i     isaerves and Surplus     (150.99)       ii     Non-Controlling Interests     -   | v Others  | 200.25  | 203.9          |
| i Deferred Tax Assets (net)<br>Other Non Current Assets<br>Total Non Current Assets<br>Investor Assets<br>Investor Investor<br>i Trade Receivables<br>i Cash and Cash Equivalents<br>v Bank balances other than above<br>v Loans and Advances<br>c Current Tax Assets (net)<br>d Other Current Assets<br><b>Total Current Assets</b><br><b>EQUITY AND LIABILITIES</b><br><b>EQUITY AND LIABILITIES</b><br><b>EQUITY AND LIABILITIES</b><br><b>EQUITY AND LIABILITIES</b><br><b>I</b> Reserves and Surplus<br>i Reserves and Surplus<br>i Non-Controlling Interests<br><b>I</b> Non-Controlling Interests<br><b>I</b> Non-Controlling Interests<br><b>I</b> Cotal Current Assets<br><b>I</b> Non-Controlling Interests<br><b>I</b> Non-Controlling Interest<br><b>I</b> Non-Controlling Interest<br><b>I</b> Non-Controlling Interest<br><b>I</b> Non-Controlling Interest<br><b>I</b> Non-Controlling Interest<br><b></b>   | v Loans   | -   | -              |
| j       Other Non Current Assets       -         Total Non Current Assets         1,014.51       1,018         2       Current Assets       -         a       Inventories       -         b       Financial Assets       -         i       Investments       -         i       Trade Receivables       212.45         i       Cash and Cash Equivalents       0.93         v       Bank balances other than above       -         v       Loans and Advances       134.00       134.00         vi       Other financial assets       52.59       33         c       Current Tax Assets (net)       -       -         d       Other Current Assets       705.51       703         d       Other Current Assets       1,480.87       1,480         b       Ther Equity       -       -         a       Equity Share Capital       1,480.87       1,480         b       Other Equity       -       -         i       Share Warrants       -       -         ii       Reserves and Surplus       (150.99)       (300         ii       Non-Controlling Interests       - <td< td=""><td>vi Others</td><td>-</td><td>-</td></td<>  | vi Others   | -   | -              |
| j       Other Non Current Assets       -         Total Non Current Assets         1,014.51       1,018         2       Current Assets       -         a       Inventories       -         b       Financial Assets       -         i       Investments       -         i       Trade Receivables       212.45         i       Cash and Cash Equivalents       0.93         v       Bank balances other than above       -         v       Loans and Advances       134.00       134.00         vi       Other financial assets       52.59       33         c       Current Tax Assets (net)       -       -         d       Other Current Assets       705.51       703         d       Other Current Assets       1,480.87       1,480         b       Ther Equity       -       -         a       Equity Share Capital       1,480.87       1,480         b       Other Equity       -       -         i       Share Warrants       -       -         ii       Reserves and Surplus       (150.99)       (300         ii       Non-Controlling Interests       - <td< td=""><td>i Deferred Tax Assets (net)</td><td>-</td><td>-</td></td<>  | i Deferred Tax Assets (net)   | -   | -              |
| Total Non Current Asets1,014.511,0182Current Assets-1a Inventories-1b Financial Assets-1i Investments-1ii Trade Receivables212.45214ii Cash and Cash Equivalents0.930v Bank balances other than abovev Loans and Advances134.00134vi Other financial assets52.5933c Current Tax Assets (net)dOther Current Assets705.51703t Equity And LIABILITIES1,480.871,480a Equity Share Capital1,480.871,480b Other Equityis Reserves and Surplus(150.99)(300ii Non-Controlling Interests  | a construction of the second | -   | -              |
| a Inventories - 12<br>b Financial Assets 12<br>i Investments   | Total Non Current Asets   | 1,014.51  | 1,018.7        |
| a Inventories - 12<br>b Financial Assets   | 2 Current Accets  |   |                |
| b Financial Assets<br>i Investments<br>i Trade Receivables<br>i Cash and Cash Equivalents<br>v Bank balances other than above<br>v Loans and Advances<br>i Other financial assets<br>c Current Tax Assets (net)<br>d Other Current Assets<br><b>Total Current Assets</b><br><b>Total Assets</b><br><b>Total Assets</b><br><b>Total Assets</b><br><b>1</b> ,720.02<br><b>1</b> ,722<br><b>2</b><br><b>EQUITY AND LIABILITIES</b><br><b>EQUITY AND LIABILITIES</b><br><b>1</b><br><b>Equity</b><br>a Equity Share Capital<br>b Other Equity<br>i Share Warrants<br>i Reserves and Surplus<br>(150.99) (300)<br>i Non-Controlling Interests   |   |   | 12.9           |
| i Investments<br>i Trade Receivables<br>i Trade Receivables<br>i Cash and Cash Equivalents<br>v Bank balances other than above<br>v Loans and Advances<br>v Loans and  |   |   | 12.9           |
| ii Trade Receivables 212.45 214<br>ii Cash and Cash Equivalents 0.93 0<br>Bank balances other than above -<br>Loans and Advances 134.00 134<br>i Other financial assets 52.59 37<br>c Current Tax Assets (net) -<br>d Other Current Assets 1,720.02 1,722<br>EQUITY AND LIABILITIES 1,720.02 1,722<br>EQUITY AND LIABILITIES 1,720.02 1,722<br>Equity Share Capital 1,480.87 1,480<br>b Other Equity -<br>i Share Warrants -<br>ii Reserves and Surplus (150.99) (300  |   | -   | -              |
| ii Cash and Cash Equivalents 0.93 0.0<br>Bank balances other than above - 134.00 134<br>V Loans and Advances 134.00 134<br>i Other financial assets 52.59 335<br>c Current Tax Assets (net) - 0<br>d Other Current Assets 705.51 703<br>Total Current Assets 705.51 703<br>EQUITY AND LIABILITIES 1.720.02 1,722<br>EQUITY AND LIABILITIES 1.720.02 1,722<br>Equity Share Capital 1,480.87 1,480<br>b Other Equity - 1<br>i Share Warrants - 1<br>i Reserves and Surplus (150.99) (300<br>i Non-Controlling Interests - 1  |   | 212 45  | 214.2          |
| v       Bank balances other than above       -         v       Loans and Advances       134.00         v       Loans and Advances       134.00         v       Loans and Advances       52.59         v       Current Tax Assets (net)       -         v       Current Assets       305.54         Other Current Assets       705.51       703         Total Current Assets       1,720.02       1,722         EQUITY AND LIABILITIES       -       -         Equity       -       -         a       Equity Share Capital       1,480.87       1,480         b       Other Equity       -       -       -         i       Share Warrants       -       -       -         ii       Reserves and Surplus       (150.99)       (300         ii       Non-Controlling Interests       -       -       -  |   |   | 0.4            |
| v Loans and Advances 134.00 134<br>vi Other financial assets 52.59 33<br>c Current Tax Assets (net)  |   | 0.95  | 0.4            |
| <ul> <li>vi Other financial assets<br/>Current Tax Assets (net)</li> <li>Other Current Assets</li> <li>Other Current Assets</li> <li>Total Current Assets</li> <li>Total Current Assets</li> <li>Total Assets</li> <li>Total Assets</li> <li>1,720.02</li> <li>1,722</li> <li>Equity<br/>Equity Share Capital</li> <li>Other Equity</li> <li>Share Warrants</li> <li>Reserves and Surplus</li> <li>Non-Controlling Interests</li> </ul>  |   | 124.00  | 124.0          |
| c       Current Tax Assets (net)       -         0       305.54       304         0       Total Current Assets       705.51       703         Total Assets       1,720.02       1,722         EQUITY AND LIABILITIES       Equity       -       -         Equity       1,480.87       1,480       1,480         b       Other Equity       -       -       -         i       Share Warrants       -       -       -       -       -         ii       Non-Controlling Interests       -   |   | Annual | 134.0          |
| d Other Current Assets<br>Total Current Assets<br>Total Current Assets<br>Total Assets<br>1,720.02<br>4<br>EQUITY AND LIABILITIES<br>Equity<br>a Equity Share Capital<br>b Other Equity<br>i Share Warrants<br>ii Reserves and Surplus<br>ii Non-Controlling Interests<br>A Controlling Interests<br>A Cont   |   | 52.59   | 37.7           |
| Total Current Assets705.51703Total Assets705.51703Total Assets1,720.021,722EQUITY AND LIABILITIESEquity<br>a Equity Share Capital1,480.871,480b Other Equity<br>i Share Warrantsi Reserves and Surplus(150.99)(300)ii Non-Controlling Interests  |   | -   | -              |
| Total AssetsEQUITY AND LIABILITIESEquityEquitya Equity Share Capital0 Other Equityi Share Warrantsii Reserves and Surplusii Non-Controlling Interests  |   |   | 304.3          |
| EQUITY AND LIABILITIES       Equity       a Equity Share Capital       b Other Equity       i Share Warrants       ii Reserves and Surplus       iii Non-Controlling Interests   | Total Current Assets  | 705.51  | 703.7          |
| I Equity     1,480.87       a Equity Share Capital     1,480.87       b Other Equity     -       i Share Warrants     -       ii Reserves and Surplus     (150.99)       ii Non-Controlling Interests     -  | Total Assets  | 1,720.02  | 1,722.5        |
| a Equity Share Capital     1,480.87     1,480       b Other Equity     -     -       i Share Warrants     -     -       ii Reserves and Surplus     (150.99)     (300       ii Non-Controlling Interests     -   | EQUITY AND LIABILITIES  |   |                |
| a Equity Share Capital     1,480.87     1,480       b Other Equity     -     -       i Share Warrants     -     -       ii Reserves and Surplus     (150.99)     (300       ii Non-Controlling Interests     -   | 1 Equity  |   |                |
| b Other Equity -<br>i Share Warrants -<br>ii Reserves and Surplus (150.99) (300<br>ii Non-Controlling Interests -  |   | 1,480.87  | 1,480.8        |
| i Share Warrants -<br>ii Reserves and Surplus (150.99) (300<br>ii Non-Controlling Interests -  |   | -   | -              |
| ii Reserves and Surplus (150.99) (300<br>ii Non-Controlling Interests -  |   | -   |                |
| ii Non-Controlling Interests -   |   | (150.99)  | (300.8         |
|  |   |   |                |
| Tatal Faults 1 200 00 1 1 100  | Total - Equity  | 1,329.88  | 1,180.04       |



-

|   | Total - Equity and Liabilities | 1,720.02 | 1,722.53 |
|---|--------------------------------|----------|----------|
|   | Total Current Liabilities      | 383.06   | 537.93   |
| d Currenr Tax Liabilities (net)                 |                                | -        | -        |
| c Provisions                                    |                                | 0.00     | 0.00     |
| b Other Current Liabilities                     |                                | 96.83    | 275.1    |
| ii Other Financial Liabilities                  |                                | -        | -        |
| ii Trade Payables                               |                                | 12.15    | 28.72    |
| i Borrowings                                    |                                | 274.07   | 234.05   |
| a Financial Liabilities                         |                                |          |          |
| Current Liabilities                             |                                |          |          |
|   | Total Non Current Liabilities  | 7.08     | 4.50     |
| d Other Non Current Liabilities                 | Tatal New Construction         | -        | -        |
| c Deferred Tax Liabilities (net)                |                                | -        | -        |
| b Provisions                                    |                                | 7.08     | 4.5      |
| iii Other Financial Liabilities                 |                                | -        | -        |
| ii Trade Payables                               |                                | _        | 1.0      |
| i Borrowings                                    |                                | -        | _        |
| a Financial Liabilities                         |                                |          |          |
| 2 <u>Liabilities</u><br>Non Current Liabilities |                                |          |          |

For DR HABEEBULLAH LIFE SCIENCES LIMITED

Place: Hyderabad Date: 19/05/2022

K. Krishnam Raju Executive Chairman (DIN 00874650)

C

.4

## DR HABEEBULLAH LIFE SCIENCES LIMITED 6-3-354/13/B2, Suryateja Apartments, Hindinagar, Punjagutta Hyderabad 500082, Telangana State, INDIA

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2022

| PARTICULARS   | Year Ended<br>March 31, 2022 | Year Ended Marc<br>31, 2021   |
|---|------------------------------|---|
|   |                              | 51, 2021  |
| A. CASH FLOW FROM OPERATING ACTIVITIES :  |                              |   |
| Net profit before tax<br>Adjustment for:  | 14,983,901                   | (6,288,573  |
|   |                              |   |
| Depreciation and Amortisation<br>Interest Expenses  | 53,611                       | 96,014  |
| Interest Expenses   | -                            |   |
| Cash Flows from Operations before changes in assets and liabilities                                   | 15,037,512                   |   |
| Movements in Working Capital::  | 13,037,312                   | (6,192,559  |
| (Increase)/ Decrease in trade receivables   |                              |   |
| (Increase)/ Decrease in Short Term Loans and Advances   | 180,302                      | 325,722   |
| (Increase)/ Decrease in Short Term Loans and Advances<br>(Increase)/ Decrease in other Current Assets |                              | (H)   |
| (Increase)/ Decrease in other other financial Assets  | (115,047)                    | (7,173  |
| (Increase)/ Decrease in Inventories   | (1,481,780)                  | (1,366,531  |
| Increase /(Decrease) in Trade Payables  | 1,292,128                    | 19,273  |
| Increase/ (Decrease) in Other current liabilities   | (1,657,004)                  | (177,649  |
| Increase/ (Decrease) in Current Provisions  | (17,831,926)                 | 5,195,363   |
| Change in Working Capital   | (96)                         | (242,944  |
| change in working capital   | (19,613,423)                 | 3,746,061   |
| Changes in non current assets and liabilities   |                              |   |
| Decrease/(Increase) in other financials Assets  | 272.002                      | -   |
| (Decrease)/Increase in Long Term Borrowings   | 373,662                      | 29,000  |
| (Decrease)/Increase in Long Term Provisions   | 252 146                      | -   |
| Changes in non current assets and liabilities   | 252,146<br>625,808           | (993,399)<br>(964,399)  |
| ash Concentral From Concentration   |                              | (504,555)   |
| ash Generated From Operations<br>ess: Taxes paid  | (3,950,103)                  | (3,410,897)   |
| ess. Taxes para   |                              | 4   |
| Net Cash from operating activities(A)   | (3,950,103)                  | (3,410,897)   |
| . CASH FLOW FROM INVESTING ACTIVITIES   |                              |   |
| (Increases) / Decrease in Fixed assets and Capital Work In progress                                   |                              | and here and  |
| Bank Balances not considered as Cash and Cash equivalents   |                              | (2,272,849)   |
| Investment in equity Shares   |                              | = •:  |
|   |                              |   |
| Balance of Unclaimed Dividend   |                              |   |
| et cash used in Investing activities (B)  |                              | (2,272,849)   |
| CASH FLOW FROM FINANCING ACTIVITIES   |                              |   |
| Increase / (Decrease) in Share Capital  |                              |   |
| Increase / (Decrease) in Borrowings   |                              | -   |
| Interest paid   | 4,002,000                    | 5,490,000   |
| et cash Flow from Financing Activities ( C )  | 4,002,000                    | 5,490,000   |
| Effect of exchange differences on translation of foreign currency cash and i                          |                              |   |
| et Increase/(Decrease) in cash & cash equivalents [A+B+C]   |                              |   |
| ASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR   | 51,897                       | (193,745)   |
| SH & CASH EQUIVALENTS AT THE END OF THE YEAR  | 41,317                       | 235,061   |
|   | 93,213                       | 41,317  |
| for and on beha<br>for DR HABEEBULLAH LI  | alf of the Board ES          | Cia   |
| 40  | 13/                          | 13  |
| 19  | 12                           | ES  |
|   | 181                          | 151   |
| (K.Krishi   | nam Rajus                    | 1.01  |
| Whole-time Direct   | tor & Chairman O             | */  |
| DIN: 00   | 374650                       | and the second se |
| ce: Hyderabad   | the country                  |   |



#### Date: 19.05.2022

| 1.BSE Limited              | 2.Metropolitan Stock Exchange of India Limited                           |
|----------------------------|--|
| P.J. Towers, Dalal Street, | Vibgyor Towers, 4 <sup>th</sup> floor, Plot No. C62, Opp. Trident Hotel, |
| Mumbai – 400001            | BandraKurla Complex, Bandra (E), Mumbai- 400098                          |

Dear Sir/Madam,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, K. Krishnam Raju, Chairman & Whole-time Director of Dr Habeebullah Life Sciences Limited hereby declare that the statutory Auditors of the company, M/s. A.M. Reddy & D.R. Reddy., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company for the quarter and year ended 31<sup>st</sup> March, 2022.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours sincerely, For DrHabeebullah tife Sciences Limited

K. Krishnam Raju Chairman & Whole-time Director DIN: 00874650

# Dr Habeebullah Life Sciences Ltd

**Regd.** Off & Corp Off : 6-3-354/13/B2,, Suryateja Apartments, Hindinagar, Punjagutta, Hyderabad-500082 .**CIN No.**: L85110TG1996PLC099198. Email: <u>cs@drhlsl.com</u>, <u>info@drhlsl.com</u>, <u>pcproductsindia@gmail.com</u> **Contact No.**: **9490424639**, Website : www.drhlsl.com

To,



## A.M. REDDY & D.R. REDDY CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly Financial Results and Year to Date Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To the Board of Directors of Dr Habeebullah Life Sciences Limited

Report on the Audit of Financial Results

Opinion

We have audited the accompanying annual financial results of **Dr Habeebullah Life Sciences Limited**(hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2022('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- . (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
  - (ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards)Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other financial information of the Company for the year ended March 31, 2022.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

H.O.: #14/186, Flat No. 203, Anantha Sai Residency, Kamalnagar, Anantapur-515 001 I Phone : 08554-231666 B.O.: H.No. 3-6-640/1/C, 4th Floor, Street No.9, Himayatnagar, Hyderabad - 500 029. I Phone : 040-40077393 Cell: +91-9848032382, 94944 94458, 98660 95897 I Email : rkreddy1999#yahoo.com, carsrreddy@gmail.com; ramachandra\_ca@yahoo.com We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Financial Results

This Statement has been prepared on the basis of the annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

### Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



#### **Other Matters**

The Statement include the results for the quarter ended March 31, 2022being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

The Annual Financial results dealt with by this report have been prepared for the express purpose of filing with stock exchanges on which company shares are listed. These results are based on should be read with the audited financial statements of the company for the year ended March 31, 2022.

Our Opinion is not modified in respect of the above matter.

Hyderabad

ered Accountat

For A.M REDDY & D.R REDDY Chartered Accountants ICAI Firm Registration No.0090685

D. Rama Krishna Reddy Partner Membership No. 209211 UDIN: 22209211AJGLBW9448 Place: Hyderabad Date: May 19, 2022